Literature DB >> 6149030

Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics.

G P Stoehr, P D Kroboth, R P Juhl, D B Wender, J P Phillips, R B Smith.   

Abstract

The effects of low-dose estrogen oral contraceptives (OC) on the elimination of the oxidized benzodiazepines triazolam (TRZ) and alprazolam (ALP) and the conjugated benzodiazepines temazepam (TMZ) and lorazepam (LOR) were studied in two parallel crossover studies of 20 women each. Women taking OC steroids containing low doses of estrogen and women matched for age, weight, and cigarette smoking received single oral doses of TRZ (0.5 mg) and TMZ (30 mg) or ALP (1 mg) and LOR (2 mg). Kinetics were determined as plasma concentrations during 48 hr after dosing. OCs inhibited the metabolism of ALP: The AUC increased and the elimination rate constant was greater in users of OCs. For TRZ, which has an intermediate extraction ratio, the AUC was increased by OCs but not significantly so. In contrast, OCs decreased the AUC for TMZ and the elimination rate constants for LOR and TMZ. The AUC of LOR was not affected by OCs. Low-dose estrogen OCs may therefore inhibit the metabolism of some oxidized benzodiazepines and accelerate the metabolism of some conjugated benzodiazepines.

Entities:  

Keywords:  Contraception; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods--pharmacodynamics; Drugs--pharmacodynamics; Family Planning; Oral Contraceptives, Low-dose--pharmacodynamics; Oral Contraceptives--pharmacodynamics; Treatment

Mesh:

Substances:

Year:  1984        PMID: 6149030     DOI: 10.1038/clpt.1984.240

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

1.  Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.

Authors:  S Palovaara; K T Kivistö; P Tapanainen; P Manninen; P J Neuvonen; K Laine
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

2.  Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon.

Authors:  H Mönig; C Baese; H T Heidemann; E E Ohnhaus; H M Schulte
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

3.  Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin.

Authors:  L O Eriksson; E Wåhlin-Boll; H Liedholm; P Seideman; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 5.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

7.  Paracetamol metabolism in pregnancy.

Authors:  J O Miners; R A Robson; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

8.  Propranolol does not alter flutoprazepam kinetics and metabolism in the rat.

Authors:  I Conti; S Sarati; S Caccia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

9.  Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal.

Authors:  J I Macdonald; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects.

Authors:  Sanna Palovaara; Gunnel Tybring; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.